(0913–0938) RA – Treatment Poster II

Sunday, November 13, 2022

9:00 AM – 10:30 AM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

9:00 AM – 10:30 AM Eastern Time

Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Abstract Poster Presenter: Karam Jabri, MD – SUNY Downstate Medical Center
9:00 AM – 10:30 AM Eastern Time

The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
Abstract Poster Presenter: Kaoru Takase-Minegishi, MD, PhD – Yokohama City University Graduate School of Medicine
9:00 AM – 10:30 AM Eastern Time

Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
Abstract Poster Presenter: Renske Hebing, MSc – Reade
9:00 AM – 10:30 AM Eastern Time

Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Abstract Poster Presenter: Charis Meng, MD – Hospital for Special Surgery
9:00 AM – 10:30 AM Eastern Time

Fifty-two-week Results from a Phase 3, Randomized, Double-blind, Active-controlled Clinical Trial to Compare BAT1806/BIIB800, a Proposed Tocilizumab Biosimilar, with a Tocilizumab Reference Product in Subjects with Moderate to Severe RA with an Inadequate Response to Methotrexate
Abstract Poster Presenter: Xiaomei Leng, MD, PhD – NA
9:00 AM – 10:30 AM Eastern Time

Efficacy and Safety of Filgotinib in Patients with Inadequate Response to Methotrexate, with 4 or < 4 Poor Prognostic Factors: A Post Hoc Analysis of the FINCH 1 Study
Abstract Poster Presenter: BERNARD COMBE, MD, PhD – Montpellier University
9:00 AM – 10:30 AM Eastern Time

Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
Abstract Poster Presenter: Siddharth Jain, MD, MBBS, DM, MRCP – Postgraduate Institute of Medical Education and Research, Chandigarh, India
9:00 AM – 10:30 AM Eastern Time

Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Abstract Poster Presenter: Ji-Won Kim, MD – Ajou university school of medicine
9:00 AM – 10:30 AM Eastern Time

Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Abstract Poster Presenter: Ivan Arias de la Rosa, PhD – Reina Sofia Hospital / IMIBIC / University of Cordoba
9:00 AM – 10:30 AM Eastern Time

Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib
Abstract Poster Presenter: Nuria Barbarroja, PhD – University of Cordoba
9:00 AM – 10:30 AM Eastern Time

WITHDRAWN
9:00 AM – 10:30 AM Eastern Time

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid
Abstract Poster Presenter: Aakash Patel, MD, BS – University of Alabama at Birmingham
9:00 AM – 10:30 AM Eastern Time

Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis
Abstract Poster Presenter: Mengdong He, MHS – UCLA David Geffen School of Medicine
9:00 AM – 10:30 AM Eastern Time

Methotrexate Polyglutamates Exposure - Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Abstract Poster Presenter: Renske Hebing, MSc – Reade
9:00 AM – 10:30 AM Eastern Time

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Abstract Poster Presenter: Nehad Soloman, MD – Arizona Arthritis & Rheumatology Associates, P.C.
9:00 AM – 10:30 AM Eastern Time

Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
Abstract Poster Presenter: Namrata Singh, MD, MSc – University of Washington
9:00 AM – 10:30 AM Eastern Time

Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases
Abstract Poster Presenter: Martin Aringer, MD – University Medical Center and Faculty of Medicine TU Dresden
9:00 AM – 10:30 AM Eastern Time

Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Abstract Poster Presenter: Alberto Sulli, MD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.
9:00 AM – 10:30 AM Eastern Time

Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Abstract Poster Presenter: Rashmi Roongta, MD, MBBS, DM – Institute of Postgraduate Medical Education and Research
9:00 AM – 10:30 AM Eastern Time

Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs
Abstract Poster Presenter: Elisabeth Simader, MD – Department of Rheumatology , Medical University of Vienna
9:00 AM – 10:30 AM Eastern Time

Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Abstract Poster Presenter: Ana Triguero Martínez, BSc – Hospital Universitario La Princesa
9:00 AM – 10:30 AM Eastern Time

Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Abstract Poster Presenter: Jun Won Park, MD – Seoul National University Hospital
9:00 AM – 10:30 AM Eastern Time

Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy
Abstract Poster Presenter: Giorgio Casaburi, PhD, MSc – Exgen Inc.
9:00 AM – 10:30 AM Eastern Time

Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
Abstract Poster Presenter: Jin Kyun Park, MD – Seoul National University College of Medicine
9:00 AM – 10:30 AM Eastern Time

Conventional Synthetic DMARDs Re-treatment for Rheumatoid Arthritis Flare During Drug-free Follow-up: Rate, Dynamics and Quality of Clinical Response
Abstract Poster Presenter: Emanuele Bozzalla Cassione, MD – University of Pavia, IRCCS Policlinico San Matteo Foundation
9:00 AM – 10:30 AM Eastern Time

Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up
Abstract Poster Presenter: Emanuele Bozzalla Cassione, MD – University of Pavia, IRCCS Policlinico San Matteo Foundation